Real-life efficacy and tolerance of trametinib in BRAF-rearranged low-grade gliomas: A multicenter study. (PubMed, Eur J Cancer) - Oct 11, 2026 - "Trametinib demonstrates sustained activity in BRAF-rearranged pLGGs, including in heavily pretreated patients. This study represents the largest reported cohort of BRAF-rearranged pLGGs, expanding prior evidence and supporting a class effect of MEK inhibitors."
Clinical • Journal • Brain Cancer • Glioma • Low Grade Glioma • Oncology • Ophthalmology • Pediatrics • Solid Tumor • BRAF • NF1
|
|
Alice Metais; Amandine Bibollet; Arnault Tauziède-Espariat; Birgit Geoerger; Céline Khouri; Christelle Dufour; David Combarel; Dulanjalee Kariyawasam; Franck Bourdeaut; Isabelle Aerts; Jacques Grill; Julia Delahousse; Kévin Beccaria; Léa Guerrini-Rousseau; Lelio Guida; Marie Simbozel; Nathalie Boddaert; Noura Sellami; Pascale Varlet; Pierre Leblond; Samuel Abbou; Sandro Benichi; Thomas Blauwblomme; Volodia Dangouloff-Ros; Yassine Bouchoucha
|